Opinion on Oncology in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

KS BioMedix: an alternative route to the marketplace

Published By Datamonitor
06 Nov 2000
ResearchWire
ResearchWire

Monoclonal antibodies: sales to increase six-fold by 2005

Published By Datamonitor
19 Apr 2001
ResearchWire
ResearchWire

Colorectal cancer: sales to top $1 billion by 2007

Published By Datamonitor
08 May 2001
ResearchWire
ResearchWire

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor
16 May 2001
ResearchWire
ResearchWire

Cancer: launch of angiogenesis inhibitors will increase treatment options

Published By Datamonitor
25 May 2001
ResearchWire
ResearchWire

Cytotoxic antibiotics: sales down 4% by 2007

Published By Datamonitor
11 Jun 2001
CommentWire
CommentWire

Inex/GSK: the growing importance of drug delivery

GSK will foot the bill for Inex's development work. In a market where drug delivery is becoming as important as the compound itself, the deal represents a good chance for GSK to boost the sales and life expectancy of its drug. Inex, meanwhile, should gain significant opportunities by partnering with a leading pharmaceutical company.

Published By Datamonitor
26 Nov 2001
ResearchWire
ResearchWire

Prostate cancer: UK lowest for screening

Published By Datamonitor
17 Jan 2002
CommentWire
CommentWire

GW Pharma: more cannabis spray trials

GW is in a unique position. Although cannabis use is illegal in the UK, the company has the right to grow the drug for use in clinical trials. If the latest trials are successful, up to 40% of cancer patients may be able to benefit from the therapy. Strong trial results would leave GW in a position to gain approval for its product as early as 2004.

Published By Datamonitor
21 Jan 2002
ResearchWire
ResearchWire

Lung cancer: non small cell most common in major markets

Published By Datamonitor
14 Feb 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | » »|

No help is available.